Securities code: 300981 securities abbreviation: Zhonghong Pulin Medical Products Co.Ltd(300981) Announcement No.: 2022-003 Zhonghong Pulin Medical Products Co.Ltd(300981)
Announcement of resolutions of the 7th Meeting of the 3rd board of directors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Meetings held
Zhonghong Pulin Medical Products Co.Ltd(300981) the seventh meeting of the third board of directors was held by communication on February 23, 2022. On February 16, 2022, the company sent the meeting notice to all directors by telephone and e-mail. The meeting was presided over by Mr. sang Shujun, chairman of the board of directors, and the company’s supervisors, senior executives and relevant personnel attended the meeting as nonvoting delegates. The convening and holding of the meeting shall comply with the provisions of relevant laws, regulations and the articles of association.
2、 Deliberations of the meeting
1. Deliberated and passed the proposal on using its own idle funds to invest in low-risk financial products;
The company plans to use its own idle funds of no more than RMB 4 billion to purchase financial products with high safety, good liquidity and controllable risk under the condition of ensuring the capital demand of normal production and operation, which will be effective within one year from the date of deliberation and approval by the general meeting of shareholders. The company’s purchase of financial products with its own funds is implemented under the guarantee of the company’s normal operating capital needs, which will not affect the needs of the company’s daily capital turnover and the normal development of the company’s main business.
The independent directors have expressed their independent opinions on this. For details, please refer to the website of cninfo（ http://www.cn.info.com.cn. ）Announcement on using self owned idle funds to invest in low-risk financial products (Announcement No.: 2022-005).
The voting result is: 9 in favor, 0 against and 0 abstention.
This proposal needs to be submitted to the general meeting of shareholders of the company for deliberation and approval.
2. Deliberated and passed the proposal on cash management using temporarily idle over raised funds and their interests; The company plans to conduct cash management on the temporarily idle over raised funds and their interests before determining the investment plan without affecting the construction of the investment projects invested by the raised funds and the normal operation of the company, so as to increase the income of the company; Investment products for cash management include but are not limited to principal guaranteed financial products with high security and good liquidity, such as structural deposits, time deposits, large certificates of deposit and reverse repurchase of government bonds. The amount of idle over raised funds and their interest shall not exceed 1.45 billion yuan, the term of a single financial product shall not exceed 12 months, and the funds can be used circularly and rolling, Valid within 12 months from the date of deliberation and approval by the general meeting of shareholders; The board of directors requests the general meeting of shareholders to authorize the chairman, general manager or their authorized personnel to sign relevant contract documents, and the specific matters shall be implemented by the Finance Department of the company.
The independent directors have expressed their independent opinions on this. For details, please refer to the website of cninfo（ http://www.cn.info.com.cn. ）Announcement on cash management using temporarily idle over raised funds and their interests (Announcement No.: 2022-006).
The voting result is: 9 in favor, 0 against and 0 abstention.
This proposal needs to be submitted to the general meeting of shareholders of the company for deliberation and approval.
3. The proposal on the company and its subsidiaries applying to the bank for comprehensive credit line in 2022 and the company providing guarantee for its subsidiaries applying for comprehensive credit line was deliberated and adopted;
In 2022, the company and its subsidiaries intend to apply to relevant banks for a comprehensive credit line of no more than 4 billion yuan in total, which shall be subject to the credit line actually approved by each bank. Among them, the total credit line applied to the above financial institutions by means of self owned assets mortgage and pledge shall not exceed 1 billion yuan, and each mortgage and pledge subject can be used within the scope of the total mortgage and pledge line; Among them, in 2022, the company’s wholly-owned subsidiary Jiangxi zhonghongprin Medical Products Co., Ltd. (hereinafter referred to as “Jiangxi Zhonghong”) plans to apply for some comprehensive credit lines from relevant banks, and the company will provide a guarantee with a total amount of no more than 1 billion yuan to relevant banks.
In order to facilitate the implementation of the above application for credit and guarantee from the bank, the general meeting of shareholders is requested to authorize the company and Jiangxi Zhonghong to determine the specific credit and guarantee matters such as the credit subject, the mortgage and pledge subject, the selection of financial institutions and the specific variety, amount and term used in the application for credit line within the above credit line and guarantee line, The legal representative of the company or its designated agent and the legal representative of Jiangxi Zhonghong are authorized to sign relevant legal documents within the limit and handle relevant matters on behalf of the company. The signing period is from the date of deliberation and approval by the general meeting of shareholders to December 31, 2022.
This proposal has been deliberated and approved by more than two-thirds of the directors attending the board meeting, and the independent directors have expressed their independent opinions. For details, please refer to cninfo website（ http://www.cn.info.com.cn. ）Announcement on the company and its subsidiaries applying to the bank for comprehensive credit line in 2022 and the company providing guarantee for its subsidiaries applying for comprehensive credit line (Announcement No.: 2022-007).
The voting result is: 9 in favor, 0 against and 0 abstention.
This proposal needs to be submitted to the general meeting of shareholders for deliberation and approved by more than two-thirds of the voting rights held by the shareholders attending the meeting.
4. Deliberated and passed the proposal on carrying out foreign exchange derivatives trading business in 2022;
According to the needs of business development, the company and its holding subsidiaries plan to carry out foreign exchange derivatives trading business in 2022, with a balance of no more than US $500 million at any time, and the above trading quota can be recycled and rolled; The board of directors of the company requests the general meeting of shareholders to authorize the general manager as the general person in charge of foreign exchange derivatives investment business, which shall examine and approve the foreign exchange derivatives investment business within the limit, and authorize and handle relevant matters for the specific person in charge of the foreign exchange derivatives investment business of the company and its holding subsidiaries. The company and its holding subsidiaries plan to carry out foreign exchange derivatives trading business this time, which does not involve related party transactions.
The independent directors have expressed their independent opinions on this. For details, please refer to the website of cninfo（ http://www.cn.info.com.cn. ）Announcement on carrying out foreign exchange derivatives trading business in 2022 (Announcement No.: 2022-008).
The voting result is: 9 in favor, 0 against and 0 abstention.
This proposal needs to be submitted to the general meeting of shareholders of the company for deliberation and approval.
5. Deliberated and passed the proposal on formulating the derivatives investment management system;
In order to improve the corporate governance and internal control mechanism of the company, the company has formulated the derivatives investment management system in accordance with the provisions of relevant laws, regulations and normative documents such as the Shenzhen Stock Exchange gem stock listing rules (revised in 2022) and the Shenzhen Stock Exchange listed companies self regulatory guidance No. 2 – standardized operation of GEM listed companies.
For details, please refer to the company’s website (www.cn. Info. Com. CN.) Derivatives investment management system published.
The voting result is: 9 in favor, 0 against and 0 abstention.
This proposal does not need to be submitted to the general meeting of shareholders of the company for deliberation and approval.
6. Deliberated and adopted the proposal on convening the first extraordinary general meeting of shareholders in 2022;
The company plans to hold the first extraordinary general meeting of shareholders in 2022 by combining on-site voting and online voting on Monday, March 14, 2022.
For details, please refer to the company’s website (www.cn. Info. Com. CN.) Notice on convening the first extraordinary general meeting of shareholders in 2022 (Announcement No.: 2022-009).
The voting result is: 9 in favor, 0 against and 0 abstention.
3、 Documents for future reference
1. Resolutions of the 7th Meeting of the 3rd board of directors;
It is hereby announced.
Zhonghong Pulin Medical Products Co.Ltd(300981) board of directors February 23, 2002
